Akèy › Gliyòm › Massachusetts › Boston
Etid klinik pou Gliyòm nan Boston, MA
20 etid pou Gliyòm ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
MCT for the Harvard/UCSF ROBIN Center
Ap rekrite
- Brigham and Women's Hospital, Boston
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute., Boston
Targeted Pediatric High-Grade Glioma Therapy
Ap rekriteEtid obsèvasyon
- Dana-Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
Ap rekriteFaz 2
- Susan Chi, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
CARv3-TEAM-E T Cells in Glioblastoma
Ap rekriteFaz 1
- Massachusetts General Hospital Cancer Center, Boston
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Ap rekriteFaz 1 bonèVolontè an sante akeyi
- Dana-Farber Cancer Institute, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Ap rekriteFaz 1 bonè
- Dana-Farber Cancer Institute, Boston
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ap rekriteFaz 1
- Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston
CUE-102 in Recurrent Glioblastoma
Ap rekriteFaz 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
NeuroPathways Intervention for Brain Tumor Patients
Ap rekrite
- Massachusetts General Hospital Cancer Center, Boston
ASCENT Intervention for Brain Tumor Patients
Ap rekrite
- Massachusetts General Hospital Cancer Center, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital, Boston
Etid Gliyòm nan lòt vil
- New York City, NY25 etid
- Houston, TX23 etid
- Washington, DC19 etid
- Philadelphia, PA16 etid
- Columbus, OH15 etid
- Miami, FL15 etid
- San Francisco, CA14 etid
- Chicago, IL13 etid
- Durham, NC12 etid
- Seattle, WA11 etid
- Los Angeles, CA10 etid
- St. Louis, MO10 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.